1. Hivert, B, Caron, C, Petit, S, et al. Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. Blood 2012; 120: 3214–3221.
Google Scholar | Crossref | Medline2. Castillo, JJ, Gustine, JN, Meid, K, et al. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia. Br J Haematol 2019; 184: 1011–1014.
Google Scholar | Crossref | Medline3. Dicke, C, Schneppenheim, S, Holstein, K, et al. Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias. Ann Hematol 2016; 95: 945–957.
Google Scholar | Crossref | Medline4. Kapoor, P, Ansell, SM, Fonseca, R, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) guidelines 2016. JAMA Oncol 2017; 3: 1257–1265.
Google Scholar | Crossref | Medline5. Tiede, A, Rand, JH, Budde, U, et al. How I treat the acquired von Willebrand syndrome. Blood 2011; 117: 6777–6785.
Google Scholar | Crossref | Medline | ISI6. Mayerhofer, M, Haushofer, A, Kyrle, PA, et al. Mechanisms underlying acquired von Willebrand syndrome associated with an IgM paraprotein. Eur J Clin Invest 2009; 39: 833–836.
Google Scholar | Crossref | Medline7. Gertz, MA. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. Am J Hematol 2019; 94: 266–276.
Google Scholar | Crossref | Medline8. Coucke, L, Marcelis, L, Deeren, D, et al. Lymphoplasmacytic lymphoma exposed by haemoptysis and acquired von Willebrand syndrome. Blood Coagul Fibrinolysis 2014; 25: 395–397.
Google Scholar | Crossref | Medline9. Federici, AB, Rand, JH, Bucciarelli, P, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84: 345–349.
Google Scholar | Crossref | Medline | ISI10. Treon, SP, Ioakimidis, L, Soumerai, JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009; 27: 3830–3835.
Google Scholar | Crossref | Medline | ISI11. Ghobrial, IM, Xie, W, Padmanabhan, S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström macroglobulinemia. Am J Hematol 2010; 85: 670–674.
Google Scholar | Crossref | Medline12. Dimopoulos, MA, Tedeschi, A, Trotman, J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstrom’s macroglobulinemia. N Engl J Med 2018; 378: 2399–2410.
Google Scholar | Crossref | Medline13. Treon, SP, Tripsas, CK, Meid, K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med 2015; 372: 1430–1440.
Google Scholar | Crossref | Medline | ISI14. Yosef, A, Touloukian, EZ, Nambudiri, VE. Ibrutinib in the management of Waldenstrom macroglobulinemia. J Oncol Pharm Pract 2019; 25: 434–441.
Google Scholar | SAGE Journals | ISI15. Shatzel, JJ, Olson, SR, Tao, DL, et al. Ibrutinib associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost 2017; 15: 835–847.
Google Scholar | Crossref | Medline16. Wang, ML, Blum, KA, Martin, P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015; 126: 739–745.
Google Scholar | Crossref | Medline | ISI17. Ojeda-Uribe, M, Rimelen, V, Marzullo, C. Good profile of efficacy/tolerance of bortezomib or idelalisib in Waldenström macroglobulinemia associated with acquired von Willebrand syndrome. J Blood Med 2020; 11: 67–72.
Google Scholar | Crossref | Medline18. Hampel, PJ, Call, TG, Rabe, KG, et al. Disease flare during temporary interruption of ibrutinib therapy in patients with chronic lymphocytic leukemia. Oncologist 2020; 25: 974–980.
Google Scholar | Crossref | Medline